Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
| Status: | Completed |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 16 - Any |
| Updated: | 1/21/2018 |
| Start Date: | June 2007 |
| End Date: | December 2007 |
Phase I, Single and Multi-dose, Placebo Controlled, Randomized, Dose-Escalation Study to Evaluate the Safety, Tolerability and PK Profile of MP-376 Using the PARI eFlow Nebulizer for 14 Days to CF Patients
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory
tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which
has been particularly problematic to eradicate and been implicated as the major cause of
morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung
increases the local concentrations of antibiotic at the site of infection resulting in
improved antimicrobial effects compared to systemic administration. Bacterial resistance to
current aerosol antibiotic treatments indicate a need for improved therapies to treat CF
patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and
other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to
have antimicrobial effects on even the most resistant organisms and reduce the emergence of
resistant bacteria.
tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which
has been particularly problematic to eradicate and been implicated as the major cause of
morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung
increases the local concentrations of antibiotic at the site of infection resulting in
improved antimicrobial effects compared to systemic administration. Bacterial resistance to
current aerosol antibiotic treatments indicate a need for improved therapies to treat CF
patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and
other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to
have antimicrobial effects on even the most resistant organisms and reduce the emergence of
resistant bacteria.
This trial will be a single-blind, placebo-controlled, dose escalating between cohorts,
single and multi-dose, multi-center study to evaluate the safety, tolerability and
pharmacokinetic profile of levofloxacin administered as MP-376 once, then twice daily for 14
days by the aerosol route to CF patients.
single and multi-dose, multi-center study to evaluate the safety, tolerability and
pharmacokinetic profile of levofloxacin administered as MP-376 once, then twice daily for 14
days by the aerosol route to CF patients.
Inclusion Criteria:
- > 16 years of age
- Confirmed Diagnosis of Cystic Fibrosis
- Positive sputum culture for P. aeruginosa within the past 6 months
- Patients are able to elicit an FEV1 >/= 40% of predicted value at screening
- Clinically stable with no evidence of acute respiratory or lower respiratory
infections within 28 days prior to dosing
- Able to reproducibly perform spirometry measurements and be able to repeatedly produce
sputum over several hours
Exclusion Criteria:
- Use of any nebulized or systemic antibiotics within 4 weeks of starting study
- History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication
- Uncontrolled diabetes or abnormal renal function
- Tobacco use (smoking) in the last 30 days
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials